Clinical Trial Update: Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and dose range of Navarixin (MK-7123) in adults with moderate to severe chronic obstructive pulmonary disease was terminated; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Navarixin (navarixin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: TERMINATED | Results posted: 2014-09-17